X842

DRUG3 trials

Sponsors

Jiangsu Sinorda Biomedicine Co., Ltd, Cinclus Pharma Holding AB

Conditions

Erosive EsophagitisReflux Esophagitis

Phase 2

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

CompletedNCT04531475

Jiangsu Sinorda Biomedicine Co., LtdReflux Esophagitis

Start: 2020-01-21End: 2021-01-12Updated: 2025-07-17

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

CompletedNCT05055128

Cinclus Pharma Holding ABErosive Esophagitis

Start: 2021-08-11End: 2022-09-01Updated: 2026-07-01

Phase 3

The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis

CompletedNCT07079540

Jiangsu Sinorda Biomedicine Co., LtdReflux Esophagitis

Start: 2021-06-24End: 2022-12-01Updated: 2025-07-23

Related Papers

Clinical Trial: Dose‐Finding Study of Linaprazan Glurate, A Novel Potassium‐Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis

Alimentary Pharmacology & Therapeutics2025-04-041 citations